IDOR-1117-2520 is now in a Phase 2 proof-of-concept trial in psoriasis, with the potential to expand into additional autoimmune conditions where the CCR6-CCL20 pathway plays a pathogenic role.
Abstract: Energy detection is crucial during initial cell selection as it effectively assists the User Equipment (UE) in swiftly identifying a suitable Radio Frequency (RF) channel from numerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback